We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
-2.15%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$574M
AUM Growth
-$338M
Cap. Flow
-$522M
Cap. Flow %
-91.01%
Top 10 Hldgs %
44.83%
Holding
163
New
26
Increased
13
Reduced
41
Closed
50

Top Buys

Rank Stock Value
1
ELVN icon
Enliven Therapeutics
ELVN
+$12.3M
2
AMGN icon
Amgen
AMGN
+$11.3M
3
SLN
Silence Therapeutics
SLN
+$10.8M
4
VKTX icon
Viking Therapeutics
VKTX
+$9.06M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$6.59M

Top Sells

Rank Stock Value
1
CRBP icon
Corbus Pharmaceuticals
CRBP
+$10.5M
2
ALPN
Alpine Immune Sciences Inc
ALPN
+$10.4M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.14M
4
PRAX icon
Praxis Precision Medicines
PRAX
+$7.96M
5
ANNX icon
Annexon
ANNX
+$5.3M

Sector Composition

Rank Sector Weight
1 Healthcare 55.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TECX
76
Tectonic Therapeutic
TECX
$536M
$1.03M 0.18%
62,836
-2
-0% -$32
VTYX
77
DELISTED
Ventyx Biosciences
VTYX
$1.02M 0.18%
442,647
-65,000
-13% -$270K
ALLK
78
DELISTED
Allakos
ALLK
$973K 0.17%
972,675
+40,000
+4% +$47.5K
MGNX icon
79
MacroGenics
MGNX
$233M
$850K 0.15%
200,079
-118,088
-37% -$1.15M
DCTH icon
80
Delcath Systems
DCTH
$400M
$840K 0.15%
+100,370
New +$636K
MRNS
81
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$826K 0.14%
706,154
+168,229
+31% +$421K
PRQR icon
82
ProQR Therapeutics
PRQR
$244M
$803K 0.14%
483,583
– –
VERU icon
83
Veru
VERU
$35.5M
$796K 0.14%
94,638
– –
LYEL icon
84
Lyell Immunopharma
LYEL
$318M
$763K 0.13%
+26,303
New +$1.25M
CLYM
85
Climb Bio
CLYM
$693M
$711K 0.12%
+100,000
New +$666K
AVTX icon
86
Avalo Therapeutics
AVTX
$1.01B
$682K 0.12%
54,730
+8,082
+17% +$105K
ABOS icon
87
Acumen Pharmaceuticals
ABOS
$152M
$645K 0.11%
266,435
– –
MIST icon
88
Milestone Pharmaceuticals
MIST
$129M
$620K 0.11%
466,019
– –
JBIO
89
Jade Biosciences
JBIO
$1.18B
$611K 0.11%
10,513
– –
RAPT
90
CALL
DELISTED
RAPT Therapeutics
RAPT
$610K 0.11%
250
-10,650
-98% -$492K
IMTX icon
91
Immatics
IMTX
$1.23B
$574K 0.1%
49,415
– –
IMUX icon
92
Immunic
IMUX
$178M
$548K 0.1%
49,350
-111,888
-69% -$1.39M
AMLX icon
93
Amylyx Pharmaceuticals
AMLX
$2.19B
$522K 0.09%
274,551
-56,900
-17% -$110K
KZR
94
DELISTED
Kezar Life Sciences
KZR
$521K 0.09%
86,899
– –
RAPT
95
DELISTED
RAPT Therapeutics
RAPT
$472K 0.08%
19,328
– –
VYGR icon
96
Voyager Therapeutics
VYGR
$181M
$442K 0.08%
55,857
-125,000
-69% -$1.05M
ANEB
97
DELISTED
Anebulo Pharmaceuticals
ANEB
$431K 0.08%
157,862
– –
FTH
98
Faeth Therapeutics
FTH
$746M
$403K 0.07%
+32,500
New +$676K
TARA icon
99
Protara Therapeutics
TARA
$214M
$376K 0.07%
180,712
-21,989
-11% -$64.3K
NYXH
100
Nyxoah
NYXH
$139M
$357K 0.06%
50,699
– –
2 3
4
5 6

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Ikarian Capital held 163 positions worth $574M, down 37% from $912M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Ikarian Capital withdrew a net $522M in Q2 2024, closing 50 positions and reducing 41 holdings. Its most notable exit was Alpine Immune Sciences Inc, an estimated $10.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, up from 40% a quarter earlier.

Against the trend, Ikarian Capital opened a new position in Enliven Therapeutics worth $13.7M.

  • Ikarian Capital's largest Q2 2024 buy was Enliven Therapeutics: 586,552 shares worth $13.7M.
  • Ikarian Capital added most to Sarepta Therapeutics in Q2 2024, an estimated $6.59M increase.
  • Ikarian Capital's biggest Q2 2024 reduction was Corbus Pharmaceuticals, cutting an estimated $10.5M.
  • Ikarian Capital fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $10.4M.
  • Ikarian Capital's ten largest holdings make up 45% of its $574M portfolio in Q2 2024.
  • Ikarian Capital opened 26 new positions and closed 50 in Q2 2024.
  • Ikarian Capital's portfolio value fell 37% quarter-over-quarter to $574M.

Based on Ikarian Capital's 13F filing for Q2 2024, filed 14 Aug 2024.